Profile data is unavailable for this security.
About the company
EyePoint Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, an investigational sustained delivery intravitreal treatment in Phase II clinical trials. The Company’s commercial product, YUTIQ, is a once-every-three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye that utilizes a non-erodible formulation of Durasert. Its commercial product also includes DEXYCU, which is administered as a single dose directly into the surgical site at the end of ocular surgery and is a long-acting intraocular product for the treatment of post-operative inflammation. Its other products include ILUVIEN, Retisert, and Vitrasert.
- Revenue in USD (TTM)39.79m
- Net income in USD-102.44m
- LocationEyePoint Pharmaceuticals Inc480 Pleasant St Ste B300WATERTOWN 02472-2468United StatesUSA
- Phone+1 (617) 926-5000
- Fax+1 (617) 926-5050